vepdegestrant palbociclib in er metastatic breast cancer: phase ib trial results
Published 7 months ago • 404 plays • Length 1:56Download video MP4
Download video MP3
Similar videos
-
2:46
preliminary data on op-1250 palbociclib in advanced/metastatic er /her- breast cancer
-
3:30
final results from pallas: adjuvant palbociclib in hr /her2- early breast cancer
-
1:49
phase ib data capitello-292: capivasertib palbociclib fulvestrant in hr /her2- breast cancer
-
1:45
real-world clinical outcomes in metastatic breast cancer patients treated with palbociclib
-
1:10
palbociclib, pembrolizumab, and endocrine therapy in hr /her2- breast cancer
-
5:04
paloma-3: palbociclib and fulvestrant for hr-/her metastatic breast cancer
-
5:00
penelope-b: palbociclib with endocrine therapy in hr , her2-negative breast cancer
-
6:29
study of palbociclib after cdk & endocrine therapy in er /her2- metastatic breast cancer
-
4:40
ameera-1 updates: amcenestrant plus palbociclib for patients with er /her2– advanced breast cancer
-
1:43
composite biomarkers predictive of palbociclib endocrine treatment benefit in early breast cancer
-
39:21
bcfnz webinar: palbociclib (ibrance) for advanced or metastatic hr breast cancer - nz update
-
7:27
polaris: palbociclib for bipoc patients with her2-negative breast cancer
-
2:29
breast cancer: palbociclib in later lines
-
13:22
palbociclib and breast cancer
-
2:46
rv-471: novel protac® estrogen receptor degrader, in er breast cancer
-
2:45
paloma-3: phase 3 trial of fulvestrant with palbociclib for metastatic breast cancer
-
6:38
palbociclib in metastatic breast cancer. discussion of the paloma-2 results.
-
1:25
ameera-5: amcenestrant palbociclib for previously untreated er /her2- advanced breast cancer
-
5:43
cdk 4/6 inhibitor, palbociclib, for the treatment of metastatic breast cancer